Pure Financial Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $448K | Buy |
4,952
+2,364
| +91% | +$198K | 0.01% | 398 |
|
|
2026
Q1 | $207K | Buy |
2,588
+41
| +2% | +$3.38K | ﹤0.01% | 538 |
|
|
2025
Q4 | $217K | Buy |
+2,547
| New | +$209K | ﹤0.01% | 493 |
|
|
2023
Q4 | – | Sell |
-3,061
| Closed | -$212K | – | 307 |
|
|
2023
Q3 | $212K | Buy |
3,061
+357
| +13% | +$28.7K | 0.01% | 248 |
|
|
2023
Q2 | $255K | Sell |
2,704
-15,111
| -85% | -$1.31M | 0.01% | 227 |
|
|
2023
Q1 | $1.47M | Buy |
17,815
+100
| +0.6% | +$7.86K | 0.07% | 101 |
|
|
2022
Q4 | $1.32M | Sell |
17,715
-28
| -0.2% | -$2.16K | 0.07% | 104 |
|
|
2022
Q3 | $1.47M | Buy |
17,743
+20
| +0.1% | +$1.92K | 0.09% | 93 |
|
|
2022
Q2 | $1.69M | Buy |
17,723
+1,889
| +12% | +$196K | 0.1% | 90 |
|
|
2022
Q1 | $1.86M | Sell |
15,834
-18
| -0.1% | -$2.02K | 0.09% | 84 |
|
|
2021
Q4 | $2.05M | Sell |
15,852
-23
| -0.1% | -$2.68K | 0.1% | 77 |
|
|
2021
Q3 | $1.8M | Buy |
15,875
+59
| +0.4% | +$6.73K | 0.14% | 75 |
|
|
2021
Q2 | $1.64M | Sell |
15,816
-510
| -3% | -$48.1K | 0.13% | 81 |
|
|
2021
Q1 | $1.37M | Sell |
16,326
-30
| -0.2% | -$2.54K | 0.14% | 79 |
|
|
2020
Q4 | $1.49M | Buy |
16,356
+30
| +0.2% | +$2.49K | 0.18% | 76 |
|
|
2020
Q3 | $1.3M | Hold |
16,326
| – | – | 0.19% | 69 |
|
|
2020
Q2 | $1.13M | Buy |
16,326
+243
| +2% | +$17.3K | 0.18% | 67 |
|
|
2020
Q1 | $1.01M | Hold |
16,083
| – | – | 0.17% | 63 |
|
|
2019
Q4 | $1.25M | Hold |
16,083
| – | – | 0.21% | 61 |
|
|
2019
Q3 | $1.18M | Hold |
16,083
| – | – | 0.21% | 60 |
|
|
2019
Q2 | $990K | Buy |
16,083
+267
| +2% | +$16.1K | 0.18% | 64 |
|
|
2019
Q1 | $1.01M | Sell |
15,816
-300
| -2% | -$17.1K | 0.19% | 62 |
|
|
2018
Q4 | $823K | Buy |
16,116
+666
| +4% | +$33.7K | 0.17% | 69 |
|
|
2018
Q3 | $897K | Buy |
+15,450
| New | +$756K | 0.2% | 62 |
|
|
2017
Q4 | – | Sell |
-14,079
| Closed | -$513K | – | 26 |
|
|
2017
Q3 | $513K | Hold |
14,079
| – | – | 0.13% | 69 |
|
|
2017
Q2 | $555K | Buy |
14,079
+1,725
| +14% | +$63K | 0.15% | 66 |
|
|
2017
Q1 | $387K | Hold |
12,354
| – | – | 0.11% | 79 |
|
|
2016
Q4 | $386K | Hold |
12,354
| – | – | 0.12% | 73 |
|
|
2016
Q3 | $496K | Hold |
12,354
| – | – | 0.16% | 58 |
|
|
2016
Q2 | $411K | Buy |
12,354
+1,869
| +18% | +$63.9K | 0.14% | 63 |
|
|
2016
Q1 | $314K | Buy |
10,485
+339
| +3% | +$9.35K | 0.11% | 73 |
|
|
2015
Q4 | $267K | Hold |
10,146
| – | – | 0.12% | 57 |
|
|
2015
Q3 | $240K | Hold |
10,146
| – | – | 0.11% | 56 |
|
|
2015
Q2 | $241K | Buy |
10,146
+1,170
| +13% | +$26.4K | 0.12% | 62 |
|
|
2015
Q1 | $213K | Buy |
+8,976
| New | +$201K | 0.07% | 56 |
|
Other funds holding EW
Pure Financial Advisors's EW Position: Q2 2026 in Review
Pure Financial Advisors increased its Edwards Lifesciences (EW) stake by 91% in Q2 2026, buying an estimated $198K and bringing the position to 4,952 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #398.
Pure Financial Advisors first reported a position in EW in Q1 2015 and has held it in 35 quarters since. The position peaked at $2.05M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Pure Financial Advisors held 4,952 shares of Edwards Lifesciences worth $448K as of Q2 2026.
- Pure Financial Advisors bought 2,364 Edwards Lifesciences shares in Q2 2026, an estimated $198K.
- Edwards Lifesciences made up 0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #398 holding.
- Pure Financial Advisors first reported a position in Edwards Lifesciences in Q1 2015 and has held it in 35 quarters since.
- Pure Financial Advisors's Edwards Lifesciences position peaked at $2.05M in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.